PerkinElmer, Inc. (PKI) Stock Analysis

PerkinElmer, Inc. (PKI) Healthcare & Pipeline Overview

PerkinElmer, Inc. delivers diagnostic and research solutions, leveraging its expertise in life sciences and applied markets. With a broad portfolio of reagents, instruments, and services, the company supports advancements in drug discovery, diagnostics, and environmental analysis, contributing to scientific and healthcare innovation globally, while facing competition from established players.

What Is the Investment Thesis for PKI?

PerkinElmer's investment thesis hinges on its diverse revenue streams across the diagnostics, life sciences, and applied solutions markets. The company's growth is driven by increasing demand for early disease detection, advancements in genomic research, and stringent environmental regulations. With a P/E ratio of 57.59 and a profit margin of 8.5%, PerkinElmer demonstrates solid profitability. Upcoming catalysts include expansion into emerging markets and strategic acquisitions to enhance its product portfolio. Potential risks include increasing competition and regulatory changes impacting diagnostic testing procedures. The company's beta of 1.10 indicates moderate volatility relative to the market.

Based on FMP financials and quantitative analysis

PKI Key Highlights

Market capitalization of $14.5B reflects PerkinElmer's significant presence in the diagnostics and life sciences sectors.

• P/E ratio of 57.59 indicates investor expectations of future earnings growth.
• Gross margin of 50.2% demonstrates PerkinElmer's ability to maintain profitability in a competitive market.
• Dividend yield of 0.32% provides a modest return to shareholders.
• The company operates through two segments: Discovery & Analytical Solutions and Diagnostics, offering a diversified revenue stream.

Who Are PKI's Competitors?

PKI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PKI's Key Strengths?

Diversified revenue streams across diagnostics, life sciences, and applied solutions.

• Strong global presence and established customer base.
• Innovative product portfolio and technological expertise.
• Experienced management team and skilled workforce.

What Are PKI's Weaknesses?

Exposure to regulatory changes and healthcare reforms.

• Dependence on research and development spending.
• Competition from larger and more established players.
• Potential for product liability claims.

What Could Drive PKI Stock Higher?

PKI catalyst: Expansion into emerging markets, particularly in Asia-Pacific and Latin America, to capitalize on growing healthcare spending.

• Development and commercialization of novel diagnostic assays for early disease detection and monitoring.
• Strategic acquisitions and partnerships to enhance product portfolio and expand market reach.
• Increasing focus on environmental testing and food safety solutions to address growing concerns about pollution and safety.

What Are the Key Risks for PKI?

Rich valuation — a P/E of 57.59 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Economic downturns and reduced healthcare spending impacting demand for PerkinElmer's products and services.
• Technological obsolescence and disruptive innovations rendering existing products and services obsolete.
• Increased competition and pricing pressures from larger and more established players.
• Supply chain disruptions and geopolitical risks impacting manufacturing and distribution operations.
• Exposure to regulatory changes and healthcare reforms impacting diagnostic testing procedures.

What Are the Growth Opportunities for PKI?

• Expansion in Emerging Markets: PerkinElmer has a significant opportunity to expand its presence in emerging markets, particularly in Asia-Pacific and Latin America. These regions are experiencing rapid growth in healthcare spending and increasing demand for advanced diagnostic and research solutions. By establishing strategic partnerships and tailoring its product offerings to local needs, PerkinElmer can capitalize on this growth opportunity. The market size for diagnostics in emerging markets is projected to reach $50 billion by 2028.
• Advancements in Genomic Research: The increasing focus on personalized medicine and the growing adoption of next-generation sequencing (NGS) technologies present a significant growth opportunity for PerkinElmer. The company can leverage its expertise in genomic workflows and its portfolio of reagents and instruments to support advancements in genomic research and clinical diagnostics. The global NGS market is expected to reach $25 billion by 2027.
• Development of Novel Diagnostic Assays: PerkinElmer can drive growth by developing and commercializing novel diagnostic assays for early disease detection and monitoring. This includes expanding its portfolio of assays for infectious diseases, oncology, and genetic disorders. By focusing on high-value targets and leveraging its expertise in assay development, PerkinElmer can capture a larger share of the diagnostics market. The market for diagnostic assays is projected to reach $90 billion by 2029.
• Strategic Acquisitions and Partnerships: PerkinElmer can accelerate its growth through strategic acquisitions and partnerships that complement its existing product portfolio and expand its market reach. This includes acquiring companies with innovative technologies in areas such as molecular diagnostics, digital pathology, and data analytics. By integrating these acquisitions and partnerships, PerkinElmer can enhance its competitive position and drive revenue growth. The company has historically grown through strategic acquisitions.
• Increasing Focus on Environmental Testing: With growing concerns about environmental pollution and food safety, PerkinElmer has an opportunity to expand its offerings in environmental testing and analysis. This includes providing analytical technologies, solutions, and services for monitoring air, water, and soil quality, as well as ensuring the safety of food products. By leveraging its expertise in analytical instrumentation and its global network of laboratories, PerkinElmer can capitalize on this growing market. The environmental testing market is expected to reach $15 billion by 2028.

What Are PKI's Competitive Advantages?

• Strong brand reputation and established market presence.
• Extensive portfolio of diagnostic and research solutions.
• Global network of laboratories and service centers.
• Proprietary technologies and intellectual property.

What Does PKI Do?

Founded in 1937 and headquartered in Waltham, Massachusetts, PerkinElmer, Inc. has evolved into a global leader providing products, services, and solutions to the diagnostics, life sciences, and applied solutions markets. The company operates through two primary segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a comprehensive suite of solutions, including reagents, informatics, and detection and imaging technologies that empower scientists to accelerate research breakthroughs in the life sciences. This segment also provides contract research and laboratory services, along with analytical technologies, solutions, and services for the environmental, food, and industrial markets, enabling customers to assess and characterize the health of air, water, and soil. PerkinElmer's solutions extend to farmers and food producers, as well as analytical instrumentation for industries such as chemical, semiconductor, energy, and petrochemical. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, infectious diseases, and other health conditions. These products are used for testing and screening genetic abnormalities, disorders, and diseases, including Down syndrome, hypothyroidism, and various metabolic conditions. PerkinElmer also develops technologies that support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. The company serves a diverse range of customers, including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies.

What Products and Services Does PKI Offer?

• Develop and manufacture diagnostic instruments and reagents.
• Provide analytical solutions for environmental and food testing.
• Offer life science research tools and services.
• Support genomic workflows with protein coupled receptor and next-generation DNA sequencing.
• Provide early detection of genetic disorders.
• Offer contract research and laboratory services.
• Develop technologies for oncology, immunodiagnostics, and drug discovery.

How Does PKI Make Money?

• Sales of diagnostic instruments, reagents, and assays.
• Revenue from analytical solutions and services.
• Income from life science research tools and services.
• Contract research and laboratory service fees.

What Industry Does PKI Operate In?

PerkinElmer operates in the medical diagnostics and research industry, which is characterized by continuous innovation, increasing regulatory scrutiny, and growing demand for personalized medicine. The market is driven by technological advancements in genomics, proteomics, and molecular diagnostics. Key trends include the rise of point-of-care testing, the adoption of digital pathology, and the increasing use of artificial intelligence in diagnostics. PerkinElmer competes with companies like ABMD, BDX, CTLT, ITCI, and KRTX, striving to maintain its market position through strategic partnerships, product development, and geographic expansion.

Who Are PKI's Key Customers?

• Pharmaceutical and biotechnology companies.
• Laboratories and research institutions.
• Public health authorities and government agencies.
• Private healthcare organizations and doctors.

Company Profile

PerkinElmer, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Prahlad R. Singh. PKI has traded publicly since 1983.

PerkinElmer, Inc. Financial Trajectory

PerkinElmer, Inc. (PKI) reported $729.7M in revenue for Q2 FY2026, reflecting 2.6% growth compared to the prior quarter. The company recorded net income of $51.8M, with diluted EPS of $464.22. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, PKI averaged $116.46 in diluted EPS.

How PerkinElmer, Inc. Is Valued

PerkinElmer, Inc. carries a market capitalization of $14.5B, placing it in the large-cap category.

Return on equity for PerkinElmer, Inc. stands at 3.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.0%, showing how much profit it generates from its asset base. PKI trades at a trailing price-to-earnings ratio of 57.59, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 4.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.72 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.0%, the inverse of the P/E and a quick read on earnings relative to price.

PerkinElmer, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.22 places it in the grey zone, a middle ground that warrants monitoring.

The most recent 12 insider filings for PerkinElmer, Inc. break down as 2 sales and 10 purchases. On net that is roughly 8K shares acquired (about $182K) — insiders putting money in tends to read as conviction.

PKI Financials

PKI Latest News

Common Questions About PKI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources